Lorazepam is one of the most versatile medications in hospital and outpatient pharmacy, and its recurring shortages force clinicians to make substitutions across a surprisingly wide range of conditions. The right alternative depends entirely on what lorazepam was being used for, because no single drug replaces it in every role. Midazolam has emerged as the most common hospital substitute, but alternatives range from other benzodiazepines to antipsychotics, anticonvulsants, barbiturates, and even non-drug therapies depending on the clinical scenario.
Why Lorazepam Is So Hard to Replace
Lorazepam occupies an unusual niche among benzodiazepines. It treats anxiety, insomnia, and seizures like its relatives, but it is also used for acute agitation in emergency departments, alcohol withdrawal, catatonia, chemotherapy-related nausea, pre-anesthetic sedation, and agitated delirium in palliative care.1Journal of Clinical Psychopharmacology. Surge of Midazolam Use in the Midst of Lorazepam Shortage Few other medications span that many indications in both injectable and oral forms.
Part of what makes lorazepam so broadly useful is its pharmacokinetic profile. It is metabolized through a simple conjugation pathway rather than the more complex oxidative metabolism that drugs like diazepam and chlordiazepoxide require. Its elimination half-life runs roughly 8 to 25 hours, and its clearance is only modestly reduced by aging or liver disease.2PubMed. Clinical pharmacokinetics of oxazepam and lorazepam That metabolic simplicity is the reason lorazepam became the default benzodiazepine for older adults and patients with liver problems. When injectable lorazepam disappears from pharmacy shelves, hospitals lose not just one drug but a workhorse that touches nearly every department.
Emergency Seizure Treatment
For status epilepticus, the most direct alternative is intramuscular midazolam. Midazolam given by injection into muscle is now considered the preferred first-line agent by many emergency medicine guidelines, in part because it saves the time required to start an IV line. It is at least as effective as intravenous lorazepam for terminating early seizures, and the practical advantage of not needing IV access can be significant when a patient is actively seizing.3PubMed Central. Strategies to innovate emergency care of status epilepticus
Diazepam is the other classic benzodiazepine for seizures, and a head-to-head pediatric trial found virtually identical seizure-cessation rates: about 73% for diazepam versus 73% for lorazepam, with no meaningful difference in the need for assisted ventilation. The one notable difference was that lorazepam caused more sedation afterward.4JAMA. Lorazepam vs Diazepam for Pediatric Status Epilepticus: A Randomized Clinical Trial So when lorazepam is unavailable, diazepam remains a well-studied backup for seizure emergencies, especially when midazolam is also in short supply.
If seizures persist after initial benzodiazepine treatment, the second-line agents are the same regardless of which benzodiazepine was used first. Levetiracetam, fosphenytoin, and valproic acid are considered equally safe and effective for established status epilepticus that does not respond to the initial dose.5PubMed Central. Strategies to innovate emergency care of status epilepticus The lorazepam shortage does not change the second-line playbook.
Acute Agitation in the Emergency Department
Emergency departments have long relied on lorazepam for patients arriving in states of severe, undifferentiated agitation. The standard approach was 1 to 2 mg given intramuscularly or intravenously, repeated as needed.6Advanced Emergency Nursing Journal. Management of Acute Agitation in the Emergency Department When that option disappears, clinicians have several alternatives, and the evidence suggests some of them may actually work faster.
Droperidol, a typical antipsychotic that fell out of favor after a controversial FDA black-box warning years ago, has been making a comeback. In a randomized double-blind trial comparing intramuscular droperidol, two doses of ziprasidone, and lorazepam for acute agitation, droperidol achieved adequate sedation at 15 minutes in about 64% of patients compared to only 29% for lorazepam. Droperidol also had lower rates of respiratory depression: roughly 12% versus 48% with lorazepam.7Academic Emergency Medicine. Randomized Double‐blind Trial of Intramuscular Droperidol, Ziprasidone, and Lorazepam for Acute Undifferentiated Agitation in the Emergency Department Those numbers surprised many clinicians, since lorazepam had been considered the gold standard for years.
Beyond droperidol, several other options exist for acute agitation:
- Haloperidol: A long-established antipsychotic used extensively for undifferentiated agitation, available intramuscularly and intravenously.
- Olanzapine: An atypical antipsychotic available as an intramuscular injection and a rapidly dissolving oral tablet, useful when patients can take something by mouth.
- Ziprasidone: Another atypical antipsychotic with intramuscular and oral forms, though the trial above found it less effective than droperidol at 15 minutes.
Antipsychotics carry their own risks, including QT prolongation and extrapyramidal symptoms, but they avoid the respiratory depression that makes benzodiazepines worrisome in agitated patients who may have consumed alcohol or other sedatives. The lorazepam shortage has, in some departments, accelerated a shift toward antipsychotic-first protocols that the evidence arguably supported even before the shortage began.
Catatonia
Catatonia is the clinical scenario where the lorazepam shortage has created the most anxiety among psychiatrists, because intravenous lorazepam has been the standard of care for decades. Patients with catatonia can be mute, immobile, and unable to eat or drink, making the condition a medical emergency in severe cases. Without IV lorazepam, clinicians have had to get creative.
Midazolam has shown promise as an alternative. A case series of six patients treated with intravenous midazolam at doses ranging from 4 to 32 mg daily found that it was at least partially effective as adjunctive therapy in five of the six cases, with no clinically significant episodes of respiratory depression, low blood pressure, or slowed heart rate.8American Journal of Health-System Pharmacy. Midazolam in the treatment of catatonia: A case series The researchers noted that the greatest improvement came after electroconvulsive therapy was started, but midazolam appeared useful as a bridge, particularly when IV lorazepam was simply not available.
An even simpler workaround has also gotten attention: oral lorazepam. While injectable lorazepam has been the form most affected by shortages, the oral formulation has sometimes remained accessible. A case report described an 18-year-old with parakinetic catatonia who was successfully stabilized and treated using oral lorazepam, highlighting that this less-documented route of administration can work when the IV and IM forms are gone.9Military Medicine. Successful Treatment of Catatonia: An Underrepresented Route of Administration Amidst a National Shortage Case Report This may sound obvious, but clinical culture around catatonia treatment had become so IV-centric that many practitioners did not immediately consider oral dosing as a viable option.
Alcohol Withdrawal
Lorazepam has been the preferred benzodiazepine for alcohol withdrawal in two vulnerable populations: older adults and people with liver disease. The reason traces back to that simple conjugation metabolism. Benzodiazepines like diazepam and chlordiazepoxide rely on oxidative metabolism, which is impaired in both aging and liver disease. When those drugs accumulate, patients can become excessively sedated or develop respiratory depression. Lorazepam and oxazepam bypass that pathway, making them safer choices in these groups.10PubMed. Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease
When lorazepam is unavailable, oxazepam is the closest metabolic equivalent, since it shares the same conjugation pathway and is similarly unaffected by liver impairment. For patients without liver disease or advanced age, diazepam and chlordiazepoxide remain effective options for alcohol withdrawal, though they require closer monitoring for sedation.
Phenobarbital has also seen a resurgence as an alcohol withdrawal treatment during lorazepam shortages. A review of six publications found that phenobarbital, whether dosed on a fixed schedule or by weight, significantly decreased intensive care unit and overall hospital stays, reduced the need for additional medications, lowered ventilator use, and prevented seizures.11PubMed Central. Phenobarbital Dosing for the Treatment of Alcohol Withdrawal Syndrome: A Review of the Literature Some hospitals have moved to phenobarbital-first protocols for alcohol withdrawal entirely, finding that outcomes are at least comparable to benzodiazepine-based approaches. Phenobarbital’s long half-life can be an advantage, creating smoother symptom control, but it also means oversedation takes longer to wear off, which demands experienced dosing.
Palliative Care and Agitated Delirium
In palliative care, lorazepam plays a specific role in managing agitated delirium in patients with advanced cancer. A randomized trial found that adding lorazepam to haloperidol produced a substantially greater reduction in agitation scores at 8 hours compared to haloperidol alone. Patients receiving the combination also needed less rescue medication, and both caregivers and nurses perceived those patients as more comfortable, with about 77 to 84% rating the combination favorably compared to roughly 30 to 37% for haloperidol alone.12JAMA. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial
When lorazepam injection became scarce, palliative care teams had to find substitutes for this specific role. One documented approach involved pharmacy staff collaborating with palliative care physicians ahead of the shortage to identify midazolam as the therapeutic alternative. The result was a substantial overall decrease in benzodiazepine use during the shortage period, partly because the teams became more deliberate about when a benzodiazepine was truly necessary. The collaborative process also helped preserve the hospital’s remaining lorazepam supply for patient populations that had no suitable alternative at all.13PubMed. Using Interdisciplinary Teams to Mitigate the Effects of Drug Shortages in Palliative Care: The Case of Lorazepam Injection
This kind of proactive substitution planning, rather than scrambling when the drug runs out, represents the approach most hospital pharmacists now recommend for shortage management.
Chemotherapy-Related Nausea
Lorazepam has been used off-label for anticipatory nausea and vomiting in chemotherapy patients, the kind that develops before or during treatment based on previous bad experiences rather than direct drug effects. Its role here is more anxiolytic than antiemetic: it blunts the conditioned anxiety response that triggers the nausea.
Modern antiemetic regimens have largely moved beyond relying on benzodiazepines as a core component. The standard of care now centers on 5-HT3 receptor antagonists like ondansetron, NK-1 receptor antagonists like aprepitant, and corticosteroids like dexamethasone.14PubMed. A systemic review on chemotherapy induced nausea and vomiting- risk and clinical management with alternative therapies These agents target the biological pathways responsible for chemotherapy-induced nausea far more directly than lorazepam ever did. For the anticipatory component specifically, behavioral interventions like guided imagery and progressive muscle relaxation are often effective. The lorazepam shortage has had less impact in oncology than in other areas precisely because the field had already moved toward more targeted antiemetics.
Anxiety and Insomnia
For patients taking lorazepam for chronic anxiety or sleep problems, the shortage creates a different kind of challenge. These are typically outpatients on long-term prescriptions who cannot simply stop the medication without risking withdrawal symptoms. The alternatives here split into pharmacological and non-pharmacological categories.
Among medications, other benzodiazepines can be substituted at equivalent doses. A clinical practice guideline on benzodiazepine tapering notes that clinicians can consider transitioning patients to a comparable dose of a longer-acting benzodiazepine when a change is needed.15PubMed Central. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits Diazepam is the most common choice for this because its long half-life produces more stable blood levels and a smoother withdrawal curve. Clonazepam is another option with a long duration of action. Both require dose adjustments because they are not milligram-for-milligram equivalent to lorazepam.
Non-benzodiazepine alternatives are worth considering, especially for patients whose original indication was insomnia. An overview of reviews found consistent evidence of effectiveness for cognitive behavioral therapy for insomnia, and the authors concluded that CBT can be considered an effective first-line therapy for adults with insomnia, followed by other behavioral interventions.16Systematic Reviews. Comparative effectiveness and safety of pharmacological and non-pharmacological interventions for insomnia: an overview of reviews Among drugs, zolpidem, doxepin, suvorexant, melatonin, trazodone, and temazepam all had evidence of effectiveness for insomnia across multiple outcomes. Despite this, surveys of primary care physicians and pharmacists suggest that benzodiazepines and antihistamines remain widely used for insomnia even though they lack long-term benefit and carry a risk of adverse reactions.17PubMed. Non-drug and drug alternatives to benzodiazepines for insomnia in primary care A shortage can sometimes be the push that moves patients toward better long-term options they might not have otherwise considered.
Switching Safely Without Triggering Withdrawal
One of the biggest practical concerns when lorazepam becomes unavailable is managing the transition for patients already taking it regularly. Abruptly stopping any benzodiazepine after weeks or months of use can cause withdrawal symptoms ranging from rebound anxiety and insomnia to seizures in severe cases. The key is finding an equivalent dose of the substitute drug and converting carefully.
For hospitalized children transitioning from continuous IV midazolam to oral benzodiazepines, a retrospective study found that standardized conversion calculations maintained withdrawal scores at consistent levels. Only about 3% of patients needed their scheduled oral benzodiazepine dose increased after conversion, and severe adverse events related to oversedation or withdrawal were minimal.18Pediatric Critical Care Medicine. Evaluation of IV to Enteral Benzodiazepine Conversion Calculations in a Pediatric Intensive Care Setting The takeaway is that when hospitals use systematic conversion protocols rather than ad hoc guessing, the switch from one benzodiazepine to another usually goes smoothly.
For outpatients, the approach is similar in principle: calculate an equivalent dose, make the switch, and monitor for breakthrough symptoms. The clinical practice guideline on benzodiazepine tapering supports transitioning to a longer-acting agent when the clinical situation calls for it.19PubMed Central. Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits Patients who have been on lorazepam for years should not attempt to switch medications on their own. Dose equivalency tables exist, but they are guidelines, and individual responses to different benzodiazepines vary enough that medical supervision during the transition matters.
Special Populations and Why Substitution Is Harder for Some
The metabolic simplicity that makes lorazepam the default for certain patients also makes it the hardest to replace in those same patients. Older adults and people with cirrhosis or other liver diseases face a narrower set of safe alternatives because many benzodiazepines depend on hepatic oxidation for clearance. Among the benzodiazepine class, oxazepam is the closest substitute because it shares lorazepam’s conjugation-based metabolism and is similarly unaffected by liver impairment.20Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. Benzodiazepines for Alcohol Withdrawal in the Elderly and in Patients With Liver Disease The catch is that oxazepam is only available orally, which limits its use in patients who cannot swallow or who need rapid onset of action.
Midazolam, the most common hospital substitute for injectable lorazepam, does undergo oxidative metabolism. In patients with normal liver function this is manageable because midazolam’s half-life is short enough that accumulation is less of a concern than with diazepam. But in patients with significantly impaired liver function, even midazolam can accumulate in ways that require dose reduction and closer monitoring. There is no perfect one-to-one replacement for lorazepam in patients with severe liver disease who need injectable benzodiazepines, which is why some hospital shortage protocols explicitly reserve remaining lorazepam stock for this population.
How Hospitals Have Managed the Shortage
The lorazepam shortage is not a single event but a recurring problem, with notable disruptions in 2022 and continuing intermittently since. Hospital pharmacy responses have generally followed a pattern: identify the highest-priority uses that have no good alternative, reserve remaining stock for those patients, and substitute midazolam or other agents everywhere else.
The palliative care collaboration described earlier is one example of this triage approach.21PubMed. Using Interdisciplinary Teams to Mitigate the Effects of Drug Shortages in Palliative Care: The Case of Lorazepam Injection During the COVID-19 pandemic, the broader drug shortage crisis prompted regulatory action, including the DEA allowing a 15% increase in aggregate production quotas for controlled substances and approving increased imports of medications like midazolam and ketamine that support mechanical ventilation.22American Journal of Health-System Pharmacy. National drug shortages worsen during COVID-19 crisis: Proposal for a comprehensive model to monitor and address critical drug shortages These measures helped but did not eliminate the problem, since drug shortages in the United States are driven by underlying manufacturing concentration, thin profit margins on generic injectables, and supply chain fragility that regulatory patches alone cannot fix.
At the institutional level, the hospitals that have fared best during lorazepam shortages tend to be those that built substitution protocols before the shortage hit rather than after. Interdisciplinary teams involving pharmacists, intensivists, psychiatrists, and palliative care specialists can pre-identify which patients genuinely need lorazepam and which can safely transition to alternatives. When the shortage arrives, the protocol is already in place and clinicians do not have to make substitution decisions under pressure with incomplete information.
The Midazolam Surge and Its Own Risks
Because midazolam has become the default replacement for lorazepam in so many settings, the lorazepam shortage has predictably increased midazolam use across hospitals.23Journal of Clinical Psychopharmacology. Surge of Midazolam Use in the Midst of Lorazepam Shortage This creates a secondary concern: if demand for midazolam spikes enough, it could face its own supply pressure. Midazolam also has a shorter duration of action than lorazepam, meaning more frequent dosing and more nursing workload in settings like ICU sedation. Its rapid onset can be an advantage for acute situations but a disadvantage when the goal is sustained, steady anxiolysis over hours.
The pharmacokinetic differences matter clinically. Lorazepam’s half-life of 8 to 25 hours means a single dose provides hours of effect.24PubMed. Clinical pharmacokinetics of oxazepam and lorazepam Midazolam’s half-life is much shorter, roughly 1.5 to 2.5 hours, so patients who were stable on scheduled lorazepam doses may need continuous midazolam infusions or very frequent intermittent doses to achieve the same effect. This is not just an inconvenience; it changes staffing needs, monitoring requirements, and medication error risk. Hospitals making the switch need to build these operational realities into their substitution protocols rather than treating the conversion as a simple dose calculation.